Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Short-term outcomes of keratoconus management with wavefront-guided normalization combined with CXL stabilization

Search Title by author or title

Session Details

Session Title: Keratoconus and Phakic IOLs

Session Date/Time: Monday 12/09/2016 | 16:30-18:30

Paper Time: 16:48

Venue: Hall C4

First Author: : E.Sunay TURKEY

Co Author(s): :    F. Helvacioglu   O. Kavalcioglu   T. Akin   A. Akyurt           

Abstract Details

Purpose:

To investigate refractive, topometric, pachymetric, and visual rehabilitation changes induced by anterior surface normalization for keratoconus by wavefront-guided excimer laser ablation in conjunction with corneal cross-linking.

Setting:

VeniVidi Eye Hospital, Istanbul, Turkey

Methods:

Twenty eyes of 15 keratoconic cases subjected to the procedure were studied for visual acuity, keratometry, pachymetry, and anterior surface irregularity indices by wavefront analysis system.

Results:

The mean age of the patients was 34.16 years (range 22 to 56 years) and the mean follow-up was 6.5 ± 1.5 months (range 1 to 19 months). Preoperatively, all eyes had irregular astigmatism ranging from 0.25 to 6.00 diopters (D). The means of pre and post operative RMS of high order aberrations were 1.91 ± 0.88 and 1.28 ± 0.70 (p=0.008).The means of pre and post operative uncorrected and corrected visual acuities were 0.08±0.02, 0.25 ±0.1 and 0.53 ±0.10, 0.76±0.19 Snellen lines respectively (p1=0.107, p2<0.001). No eyes lost Snellen lines of corrected distant visual acuity; 7 eyes (35%) had an increase of more than 4 lines. Trace haze developed in 1 eye.

Conclusions:

Short term outcomes has demonstrated that the procedure is a safe and effective method to arrest keratectasia progression and to improve corneal regularity in keratoconus management.

Financial Disclosure:

NONE

Back to previous